In 2019, a new MDM2-based PROCTAC A1874 is designed to target bromodomain-containing protein (BRD4) for degradation and stabilize the tumor suppressor P53 to inhibit cancer progression simultaneously [181]. Here, BRD4 is linked to cancer.